malecare®  Men fighting cancer together.  

Prostate Cancer, Support Groups  and Prostate Cancer Treatment

Home | Up | 攝護腺癌 | Espanol | Francais | עברית | Italiano | Portugues | Russian | Site Map | Donate to Malecare   

[EPCA test] [Vaccine] [Xinlay]

These outside  prostate cancer articles  are not necessarily endorsed by Malecare.

The Sunday Times - Britain

 
The Sunday Times 

Plant therapy offers prostate cancer cure

 
RESEARCHERS have harnessed a drug based on chlorophyll, the pigment that reacts with sunlight to produce energy in plants and make them green, to develop a treatment for prostate cancer.

The scientists injected the drug into patients and then “activated” it using tiny lasers inserted into the prostate gland. The chemically modified chlorophyll attacked and blocked the blood vessels that fed the tumours, killing the cancerous cells within days.

 

 
The technique remains experimental but trials at University College London (UCL) and in Canada suggest it has strong potential. “This is one of the most promising treatments for prostate cancer I’ve seen,” said John Trachtenberg, director of the prostate centre at Princess Margaret hospital in Toronto, who is overseeing the trials.

Prostate tumours are among the most common and deadliest of cancers in men with 30,000 new diagnoses and 10,000 deaths a year in Britain alone.

Sufferers of the disease have included Lord Runcie, the late Archbishop of Canterbury, Nelson Mandela and Bob Monkhouse, the late comedian.

The cancer can be cured if caught early but it is difficult to discriminate between cancerous and normal tissue using conventional therapies such as surgery or radiotherapy. Patients are often left incontinent and impotent because the nerves controlling urination and sexual function pass through the prostate and are destroyed along with the cancerous tissue.

The new research was prompted by these drawbacks. The technique was devised by Avigdor Scherz, in collaboration with Yoram Salomon from the department of Biological regulation. Professor Scherz is a plant biochemist based at the Weizmann Institute of Science in Israel. One of his family was stricken by cancer.

He knew that when chlorophyll was struck by light it could be induced to release a surge of “free radicals” — highly reactive molecules capable of destroying nearby cells. He reasoned that, in the darkness of the human body, a drug based on chlorophyll would remain inert unless hit by light.

“By illuminating a tumour with intense light we could activate the drug only around the cancerous cells, leaving the rest of the body unaffected,” he said.Scherz tested different chlorophyll molecules from plants and micro-organisms, finding that the best came from a bacterium that lives in sea-water.

He named the drug Tookad, Hebrew for “warmth of light”, and went into partnership with Steba Beheer NV, a Dutch firm that is sponsoring clinical trials.

Last autumn Trachtenberg enlisted 30 patients who had suffered a recurrence of prostate cancer despite being treated with radiotherapy.

In the treatment, his team inserted up to five needles into each patient’s prostate, feeding tiny fibre-optic cables through the needles. The cables were sited to illuminate the diseased prostate without affecting adjacent organs.

The patients were infused with Tookad and, as it began circulating through the body, their prostates were flooded with laser light. As the trials went on, the level of light and the number of needles were raised.

“The last 12 patients got the maximum number of needles and the highest light dose. Of those 12, a six-month biopsy has shown the cancer has gone,” said Trachtenberg. Most of the other patients also showed some benefit.

If confirmed, such results would be a significant success.

In London, the trials of Tookad are less advanced but have shown promise. Six patients have been treated using just two fibre-optic cables and 24 more cases are planned. In three cases the cancerous prostate gland has receded. The biggest hope is, however, that those treated will retain sexual function and bladder control.

Caroline Moore, a surgeon and UCL researcher who is overseeing the trial, said: “If surgery or radiotherapy fail, you often cannot do it a second time, but this approach can be repeated. It is also much less intrusive and could even be done as daycare.”



Issuers of news releases and not Malecare, its employees, contractees or assigns are solely responsible for the accuracy of the content. Links from this web site to web sites not managed by Malecare, Inc. and/or any  of its employees, associates, contractors and/or assigns do not imply endorsement or credibility of the service, information or product offered through the linked sites.
Terms and conditions, including restrictions on redistribution, apply.

What is the Prostate?
Prostate Cancer Diagnosis
Prostate Cancer PSA
Gleason Score
Staging Prostate Cancer
Prostate Carcinoma
Ask your Doctor
DNA Ploidy
Treatment Choices
Best Treatment?
Prostate Surgery Patient Hints
Prostate Cancer Surgery
Choosing A Surgeon
Laparoscopic Prostate Surgery
Radiation IMRT
HIFU for Prostate Cancer
HDR Brachytherapy
Brachytherapy
Hormone Therapy
Prostate Cancer Cryoablation
Prostate Cancer Chemotherapy
Urinary Bladder
Urinary Incontinence
Urinary Catheter Care
Self-Catheterization
Sperm Banking
Prostate Cancer Diet
Prostate Cancer News
Catalona on Prostate Cancer
Fish Oil & Prostate Cancer
Chondroitin Sulfate
Alternatives for PCa
Prostate Cancer Conference
Prostate Poetry
Prostate Cancer Books
Prostate Cancer Videos
Treatment Story
PC-SPES
Kegel Exercises
Combination Therapy
Relaxation & Visualisation
Wristband

Home | Up | Support Groups | Gay Prostate Cancer | Testicular Cancer | Enlarged Prostate | Male Breast Cancer | Tests for Men | Prostatitis | Erectile Dysfunction | Peyronie's Disease | Enlarged Breasts | Cells and Cancer | African American | Preventing Cancer | Why Support Groups? | About Malecare | Disclaimer/Privacy | New Dad | More on Cancer | Provenge

General comments or questions about prostate cancer, testicular cancer or any other men's cancer: info@malecare.com
 Comments about this web site: webmaster@malecare.com      
  Website updated on  April 2008
    Copyright © 1998-2008 Malecare, Inc.
a 501(c)3 nonprofit corporation in prostate cancer